Name: Oncosil Medical (OSL) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

OSL

Pharmaceuticals, Biotechnology & Life Sciences

Oncosil Medical

Short interest: 0.00%; 0.00 pp 30d; as of 7 Oct 2026
Reported shorts: 66
Shares on issue: 36.704M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Oncosil Medical

Oncosil Medical is a medical device company focused on the development and commercialization of innovative cancer treatments. Their primary product, OncoSil, is a brachytherapy device containing radioactive phosphorus-32, designed for the treatment of locally advanced pancreatic cancer. The company aims to improve patient outcomes and quality of life through targeted radiation therapy.

Company profile →

Oncosil Medical (ASX:OSL) has 0.00% of its shares on issue reported as short positions as of 7 Oct 2026, or about 66 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.69% in December 2024. OSL is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads OSL today

Zanger BreakoutWatchScore 18rank 1376 of 1931
CAN SLIMWatchScore 23rank 542 of 1541
Minervini Trend TemplateWatchScore 20rank 906 of 1736
Crowded-Short BreakoutNot a candidate
Quality compoundersWatchScore 25rank 574 of 1677

Prices to 13 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

OSL fundamentals

In the year to 30 Jun 2026, Oncosil Medical (ASX:OSL) recorded revenue of A$1.7M and a net loss after tax of A$10.9M. A year earlier it recorded revenue of A$1.2M and a net loss after tax of A$15.1M. Year-on-year growth: revenue +43.9% (FY). Net margin −644.5%, return on equity −268.2% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →